CLAIMS

That which is claimed is:

1. A method of prenatal diagnosis of a fetus affected by Smith-Lemli-Optiz syndrome (SLOS) comprising:

obtaining a biological sample from a woman suspected of carrying an SLOS-affected fetus;

analyzing the sample for a at least one specific SLOS analyte and a control steroid counterpart, wherein the SLOS analyte is selected from the group consisting of 8-dehydroestriol (8-DHE3) and 5β -pregn-7-ene- α , 17α , 20α -triol (7-DHPT); and

determining the ratio of the SLOS analyte to the control steroid counterpart found in the sample;

wherein a ratio of greater than 0.01 indicates that the woman carries an SLOS-affected fetus.

- 2. The method of claim 1, wherein the biological sample is a urine sample.
- 3. The method of claim 1, wherein the biological sample is serum.
- 4. The method of claim 1, wherein the sample is a blood or blood-derived sample.
- 5. The method of claim 1, wherein said analyzing comprises analysis by use of gas chromatography-mass spectrometry.
- 6. The method of claim 1, wherein said analyzing is by use of high-performance liquid chromatography/mass spectrometry.
- 7. The method of claim 1, wherein the biological sample is obtained as early as about the 11th week of gestation.
- 8. The method of claim 1, wherein the SLOS analyte is 8-DHE3 and the steroid counterpart is a estriol (E₃).

- 9. The method of claim 1, wherein the SLOS analyte is a 7-DHPT and the control steroid counterpart is a 5 β -pregnane-3 α ,17 α ,20 α -triol (PT).
- 10. The method of claim 1, wherein each of the SLOS analytes 8-DHE₃ and 7-DHPT are detected.